Hepatic encephalopathy;Hepatische enzephalopathie

Medizinische Klinik

Volumn 99, Issue 10, 2004, Pages 591-602

  Hilgard, Philip ^a   Gerken, Guido ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Ammonia; Astrocytes; HE; Hepatic encephalopathy; Liver cirrhosis

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMMONIA; ANTIBIOTIC AGENT; BENZODIAZEPINE; BRANCHED CHAIN AMINO ACID; DISACCHARIDE; GLUTAMATE AMMONIA LIGASE; GLUTAMINE; LACTULOSE; MAGNESIUM; NEOMYCIN; NEUROLEPTIC AGENT; NEUROTRANSMITTER; ORNITHINE ASPARTATE; PLACEBO; VANCOMYCIN; ZINC;

ACUTE DISEASE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BRAIN EDEMA; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HUMAN; HYPOVOLEMIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MULTIPLE ORGAN FAILURE; PORTOSYSTEMIC ANASTOMOSIS; REVIEW; TREATMENT INDICATION;

ANIMALS; DIAGNOSIS, DIFFERENTIAL; DISEASE MODELS, ANIMAL; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRCULATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PORTACAVAL SHUNT, SURGICAL;

BACTERIA (MICROORGANISMS);

EID: 6344260674     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-004-1090-x     Document Type: Review

References (98)

1. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716-21.
2. Conn HO, Bircher J. Quantifying the severity of hepatic encephalopathy. In: Conn HO, Bircher J, eds. Hepatic encephalopathy: syndromes and therapies. East Lansing: Medi Ed Press, 1993:13-26.
3. Groeneweg M, Quero JC, De BI, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998;28:45-9.
4. Lockwood AH. "What's in a name?" Improving the care of cirrhotics. J Hepatol 2000;32:859-61.
5. Fischer JE, Baldessarini RJ. False neurotransmitters and hepatic failure. Lancet 1971;2:75-80.
6. Farmer PM, Mulakkan T. The pathogenesis of hepatic encephalopathy. Ann Clin Lab Sci 1990;20:91-7.
7. Rosen HM, Yoshimura N, Hodgman JM, et al. Plasma amino acid patterns in hepatic encephalopathy of differing etiology. Gastroenterology 1977;72:483-7.
8. Fogel WA, Andrzejewski W, Maslinski C. Neurotransmitters in hepatic encephalopathy. Acta Neurobiol Exp (Warsz) 1990;50:281-93.
9. Basile AS, Jones EA. Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology 1997;25:1303-5.
10. Ferenci P, Puspok A, Steindl P. Current concepts in the pathophysiology of hepatic encephalopathy. Eur J Clin Invest 1992;22:573-81.
11. Jones EA. Ammonia, the GABA neurotransmitter system, and hepatic encephalopathy. Metab Brain Dis 2002;17:275-81.
12. Basile AS, Hughes RD, Harrison PM, et al. Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. N Engl J Med 1991;325:473-8.
13. Wilkinson SP. GABA, benzodiazepines and hepatic encephalopathy. Eur J Gastroenterol Hepatol 1995;7:323-4.
14. Venturini I, Corsi L, Avallone R, et al. Ammonia and endogenous benzodiazepine-like compounds in the pathogenesis of hepatic encephalopathy. Scand J Gastroenterol 2001;36:423-5.
15. Lockwood AH, Yap EW, Wong WH. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991;11:337-41.
16. Ong JP, Aggarwal A, Krieger D, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003;114:188-93.
17. Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab Brain Dis 2002;17:221-7.
18. Martinez-Hernandez A, Bell KP, Norenberg MD. Glutamine synthetase: glial localization in brain. Science 1977;195:1356-8.
19. Hawkins RA, Jessy J, Mans AM, et al. Effect of reducing brain glutamine synthesis on metabolic symptoms of hepatic encephalopathy. J Neurochem 1993;60:1000-6.
20. Albrecht J, Dolinska M. Glutamine as a pathogenic factor in hepatic encephalopathy. J Neurosci Res 2001;65:1-5.
21. Blei AT, Larsen FS. Pathophysiology of cerebral edema in fulminant hepatic failure. J Hepatol 1999;31:771-6.
22. Laubenberger J, Haussinger D, Bayer S, et al. Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenrerology 1997;112:1610-6.
23. Cordoba J, Gottstein J, Blei AT. Glutamine, myo-inositol, and organic brain osmolytes after portocaval anastomosis in the rat: implications for ammonia-induced brain edema. Hepatology 1996;24:919-23.
24. Ross BD, Danielsen ER, Bluml S. Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy? Dig Dis 1996;14:Suppl 1:30-9.
25. Haussinger D, Schliess F, Kircheis G. Pathogenesis of hepatic encephalopathy. J Gascroenterol Hepatol 2002;17:Suppl 3:S256-9.
26. Lang F, Busch GL, Ritter M, et al. Functional significance of cell volume regulatory mechanisms. Physiol Rev 1998;78:247-306.
27. Itzhak Y, Bender AS, Norenberg MD. Effect of bypoosmotic stress on peripheral-type benzodiazepine receptors in cultured astrocytes. Brain Res 1994;644:221-5.
28. Conn HO. Animal versus vegetable protein diet in hepatic encephalopathy. J Intern Med 1993;233:369-71.
29. Strauss E, Gomes de Sa Ribeiro MDE. Bacterial infections associated with hepatic encephalopathy: prevalence and outcome. Ann Hepatol 2003;2:41-5.
30. Arroyo V, Navasa M, Rimola A. Spontaneous bacterial peritonitis in liver cirrhosis: treatment and prophylaxis. Infection 1994;22:Suppl 3:5167-75.
31. Gunnarsdottir SA, Sadik R, Shev S, et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol 2003;98:1362-70.
32. Madrid AM, Hurtado C, Venegas M, et al. Long-term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol 2001;96:1251-5.
33. Zullo A, Hassan C, Chakrabarti P, et al. Helicobacter pylori infection and hepatic encephalopathy. Dig Liver Dis 2002;34:86.
34. Rinaldi V, Zullo A, Diana F, et al. Helicobacter pylori, hyperammonemia, and hepatic encephalopathy: is there a correlation? Am J Gastroenterol 1997;92:723-4.
35. Zullo A, Hassan C, Morini S. Hepatic encephalopathy and Helicobacter pylori: a critical reappraisal. J Clin Gastroenterol 2003;37:164-8.
36. Tromm A, Griga T, Greving I, et al. Orthograde whole gut irrigation with marmite versus paromomycine + lactulose as prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial. Hepatogastroenterology 2000;47:473-7.
37. Oster JR, Perez GO, Materson BJ, et al. Exacerbation of hepatic encephalopathy by chronic renal failure: response to maintenance hemodialysis. Clin Nephrol 1978;9:254-7.
38. Sherlock S, Walker JG, Senewiratne B, et al. The complications of diuretic therapy in patients with cirrhosis. Ann NY Acad Sci 1966;139:497-505.
39. Jalan R, Kapoor D. Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. Clin Sci (Lond) 2004;106:467-74.
40. Naranjo CA, Pontigo E, Valdenegro C, et al. Furosemide-induced adverse reactions in cirrhosis of the liver. Clin Pharmacol Ther 1979;25:154-60.
41. Laffi G, La Villa G, Carloni V, et al. Loop diuretic therapy in liver cirrhosis with ascites. J Cardiovasc Pharmacol 1993;22:Suppl 3:551-8.
42. Gerbes AL, Gulberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124:933-9.
43. Decaux G. Treatment of hyponatremic encephalopathy. J Lab Clin Med 2001;138:403.
44. Carrion JA, Bellot P, Colmenero J, et al. Large spontaneous splenorenal shunt as a cause of chronic hepatic encephalopathy. J Hepatol 2004;40:868.
45. Sakurabayashi S, Sezai S, Yamamoto Y, et al. Embolization of portal-systemic shunts in cirrhotic patients with chronic recurrent hepatic encephalopathy. Cardiovasc Intervent Radiol 1997;20:120-4.
46. Weissenborn K. Minimal hepatic encephalopathy: a permanent source of discussion. Hepatology 2002;35:494-6.
47. Nicolao F, Efrati C, Masini A, et al. Role of determination of partial pressure of ammonia in cirrhoric patients with and without hepatic encephalopathy. J Hepatol 2003;38:441-6.
48. Kuhlbusch R, Enck P, Haussinger D. [Hepatic encephalopathy: neuropsychological and neurophysiological diagnosis.] Z Gastroenterol 1998;36:1075-83.
49. Kircheis G, Wettstein M, Timmermann L, et al. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002;35:357-66.
50. Kullmann F, Hollerbach S, Lock G, et al. Brain electrical activity mapping of EEG for the diagnosis of (sub)clinical hepatic encephalopathy in chronic liver disease. Eur J Gastroenterol Hepatol 2001;13:513-22.
51. Van der Rijt CC, Schalm SW. Quantitative EEG analysis and evoked potentials to measure (latent) hepatic encephalopathy. J Hepatol 1992;14:141-2.
52. Kugler CF, Lotterer E, Petter J, et al. Visual event-related P300 potentials in early portosystemic encephalopathy. Gastroenterology 1992;103:302-10.
53. Larsen FS, Wendon J. Brain edema in liver failure: basic physiologic principles and management. Liver Transplant 2002;8:983-9.
54. Murphy N, Auzinger G, Bernel W, et al. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology 2004;39:464-70.
55. Heemann U, Treichel U, Loock J, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002;36:949-58.
56. Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999;30:890-5.
57. Watanabe A, Sakai T, Sato S, et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997;26:1410-4.
58. Liu Q, Duan ZP, Ha DK, et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004;39:1441-9.
59. Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol 2001;96:1968-76.
60. Srivastava N, Singh N, Joshi YK. Nutrition in the management of hepatic encephalopathy. Trop Gastroenterol 2003;24:59-62.
61. Amodio P, Caregaro L, Patteno E, et al. Vegetarian diets in hepatic encephalopathy: facts or fantasies? Dig Liver Dis 2001;33:492-500.
62. Eriksson LS, Conn HO. Branched-chain amino acids in the management of hepatic encephalopathy: an analysis of variants. Hepatology 1989;10:228-46.
63. Moller S, Henriksen JH. Circulatory abnormalities in cirrhosis with focus on neurohumoral aspects. Semin Nephrol 1997;17:505-19.
64. Navasa M, Casafont F, Clemente G, et al. [Consensus on spontaneous bacterial peritonitis in liver cirrhosis: diagnosis, treatment, and prophylaxis.] Gastroenterol Hepatol 2001;24:37-46.
65. Keller J, Layer F, Rosien U. Bakterielle Fehlbesiedlung. In: Layer P, Rosien S, Hrsg. Praktische Gastroenterologie. München: Urban & Fischer, 2004:219-20.
66. Weber FL Jr. Lactulose and combination therapy of hepatic encephalopathy: the role of the intestinal microflora. Dig Dis 1996;14:Suppl 1:53-63.
67. Kiba T, Numata K, Saito S. Neostigmine and polyethylene glycol electrolyte solution for the therapy of acute hepatic encephalopathy with liver cirrhosis and ascites. Hepatogastroenterology 2003;50:823-6.
68. Van Stiegmann G. Update of endoscopic band ligation therapy for treatment of esophageal varices. Endoscopy 2003;35:S5-8.
69. Ryan BM, Stockbrugger RW, Ryan JM. A pathophysiologic, gastroenterologic, and radiologic approach to the management of gastric varices. Gastroenterology 2004;126:1175-89.
70. Poynard T, Cales P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. N Engl J Med 1991;324:1532-8.
71. Laccetti M, Manes G, Uomo G, et al. Flumazenil in the treatment of acute hepatic encepbalopathy in cirrhotic patients: a double blind randomized placebo controlled study. Dig Liver Dis 2000;32:335-8.
72. Pomier-Layrargues G, Giguere JF, Lavoie J, et al. Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial. Hepatology 1994;19:32-7.
73. Goulenok C, Bernard B, Cadranel JF, et al. Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2002;16:361-72.
74. Moriya K, Kojima H, Matsumura M, et al. Disappearance of hepatic encephalopathy and improvement of liver function after surgical treatment of portal-systemic shunt in a patient with liver cirrhosis. Hepatogastroenterology 2003;50:1128-32.
75. Yamagami T, Nakamura T, Iida S, et al. Hepatic encephalopathy secondary to intrahepatic portosystemic venous shunt: balloon-occluded retrograde transvenous embolization with n-butyl cyanoacrylate and microcoils. Cardiovasc Intervent Radiol 2002;25:219-21.
76. Simmons F, Goldstein H, Boyle JD. A controlled clinical trial of lactulose in hepatic encephalopathy. Gastroenterology 1970;59:827-32.
77. Germain L, Frexinos J, Louis A, et al. [Double blind study of lactulose in 8 patients with chronic hepatic encephalopathy after portocaval shunt.] Arch Fr Mal App Dig 1973;62:293-302.
78. Als-Nidsen B, Gluud L, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev 2004;2:CD003044.
79. Kircheis G, Haussinger D. Management of hepatic encephalopathy. J Gastroenterol Hepatol 2002;17: Suppl 3:S260-7.
80. Uribe M, Berthier JM, Lewis H, et al. Lactose enemas plus placebo tablets vs. neoniycin Cablets plus starch enemas in acute portal systemic encephalopathy. A double-blind randomized controlled study. Gastroenterology 1981;81:101-6.
81. Uribe M, Canipollo O, Vargas F, et al. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 1987;7:639-43.
82. Strauss E, Tramote R, Suva EP, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992;39:542-5.
83. Orlandi F, Freddara U, Candelaresi MT, et al. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study. Dig Dis Sci 1981;26:498-506.
84. Capocaccia L, Riggio O. Nonabsorbable disaccharides plus neomycin in hepatic encephalopathy: do they enhance each other? Hepatology 1990;12:368-70.
85. Tarao K, Ikeda T, Hayashi K, et al. [Therapeutic efficacy of vancomycin hydro chloride, a nonabsorbable antibiotic, on intractable (lactulose resistant) chronic hepatic encephalopathy in cirrhotic patients.] Nippon Shokakibyo Gakkai Zasshi 1986;83:1006-14.
86. Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997;25:1351-60.
87. Gebhardt R, Beckers G, Gaunitz F, et al. Treatment of cirrhotic rats with L-ornithine-L-aspartate enhances urea synthesis and lowers serum ammonia levels. J Pharmacol Exp Ther 1997;283:1-6.
88. Rose C, Michalak A, Rao KV, et al. L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology 1999;30:636-40.
89. Staedt U, Leweling H, Gladisch R, et al. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patiente with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J Hepatol 1993;19:424-30.
90. Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998;28:856-64.
91. Naylor CD, O'Rourke K, Detsky AS, et al. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. Gastroenterology 1989;97:1033-42.
92. Marchesini G, Dioguardi FS, Bianchi GP, et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. J Hepatol 1990;11:92-101.
93. Plauth M, Egberts EH, Hamster W, et al. Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. A double-blind placebo-controlled crossover study. J Hepatol 1993;17:308-14.
94. Scholmerich J, Lohle E, Kottgen E, et al. Zinc and vitamin A deficiency in liver cirrhosis. Hepatogastroenterology 1983;30:119-25.
95. Rocchi E, Borella P, Borghi A, et al. Zinc and magnesium in liver cirrhosis. Eur J Clin Invest 1994;24:149-55.
96. Riggio O, Merli M, Capocaccia L, et al. Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis. Hepatology 1992;16;785-9.
97. Riggio O, Ariosto F, Merli M, et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial. Dig Dis Sci 1991;36:1204-8.
98. Bresci G, Parisi G, Banti S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. Eur J Med 1993;2:414-6.